Navigation Links
Telik Reports Preclinical Results at AACR Annual Meeting
Date:4/28/2009

Anti-Tumor Efficacy and Molecular Mechanism of TLK58747; Abstract # 4515

Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for enzymatic processing, and which does not release an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein).

Key findings:

  • TLK58747 inhibited the growth of nine established cell lines of various tumor types and retained its effectiveness against cancer cell lines resistant to standard cancer chemotherapeutics including adriamycin, paclitaxel, and carboplatin.
  • Treatment of human cancer cells with TLK58747 led to the activation of the DNA damage-response pathway, and produced G2/M cell cycle arrest in human solid tumor cell lines. The resulting apoptosis or senescence of these cells may depend on their p53 status.
  • In vivo, TLK58747 demonstrated significant antitumor activity both orally and parenterally against a wide variety of human tumor types, including breast, pancreatic, prostate, and colorectal carcinomas, as well as glioma and promyelocytic leukemia.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELI
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
8. Telik Announces First Quarter 2008 Financial Results
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced the ... regulatory and quality, Mohammad Hirmand, M.D., to vice,president, ... translational medicine., "As we enter Phase 3 ... the team to lead and advance our clinical ...
... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... of Vice President, Research and,Development, Oncology. Dr. Parry ... programs, including the further,development of Monogram,s proprietary VeraTag(TM) ... platform - the HERMark(TM) Breast Cancer,Assay., Dr. ...
... with Canadian Division of Global Pharmaceutical,Company, ... BASKING RIDGE, N.J., March 24 /PRNewswire/ ... Millennium Biotechnologies Group, Inc.,(OTCBB: MBTG) announced today ... distribution agreement for Resurgex(R), its nutritional formula,for ...
Cached Biology Technology:Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 2Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 4Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 2Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 3
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... When battling an epidemic of a deadly parasite, less resistance ... A freshwater zooplankton species known as ... parasite that can infect more than 60 percent of the ... evolves quickly, balancing infection resistance and reproduction. A new ...
... 2012. Metformin, a drug widely used to treat Type II ... the University of Maryland Marlene and Stewart Greenebaum Cancer Center ... Research . Primary liver cancer, or hepatocellular carcinoma, is an ... and is the fastest-growing cause of cancer-related deaths among American ...
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
Cached Biology News:Weakness can be an advantage in surviving deadly parasites, a new study shows 2Weakness can be an advantage in surviving deadly parasites, a new study shows 3Commonly used diabetes drug may help to prevent primary liver cancer 2Commonly used diabetes drug may help to prevent primary liver cancer 3Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
... The Bio-Plex maintenance, calibration, and ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Biology Products: